Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
复制标题
DOI：
10.1038/s41591-021-01325-6
复制
发表时间：
2021-06
期刊：
影响因子：
82.9
通讯作者：
Sobhani K
中科院分区：
文献类型：
--
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
在BNT 162 b2（Pfizer-BioNTech）mRNA疫苗接种者队列（n = 1，090）中，我们观察到，在既往有SARS-CoV-2感染的个体（n = 35）中，单次接种疫苗引起的刺突特异性IgG抗体水平和ACE 2抗体结合抑制反应与既往无感染的个体（n = 228）接种两次疫苗后观察到的相似。在第一次接种后，既往感染者的疫苗后症状更为突出，但在第二次接种后，两组之间的免疫学相似。在先前感染SARS-CoV-2的个体中，单次接种BNT 162 b2疫苗后的病毒特异性抗体水平与未感染个体中两次接种疫苗后的水平相似。
In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose. Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
IGA主导对SARS-COV-2的早期中和抗体反应。
影响因子：
17.1
作者：
Sterlin D;Mathian A;Miyara M;Mohr A;Anna F;Claër L;Quentric P;Fadlallah J;Devilliers H;Ghillani P;Gunn C;Hockett R;Mudumba S;Guihot A;Luyt CE;Mayaux J;Beurton A;Fourati S;Bruel T;Schwartz O;Lacorte JM;Yssel H;Parizot C;Dorgham K;Charneau P;Amoura Z;Gorochov G
通讯作者：
Gorochov G
DOI：
10.1056/nejmoa2034545
发表时间：
2021-02-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
Lumley SF;O'Donnell D;Stoesser NE;Matthews PC;Howarth A;Hatch SB;Marsden BD;Cox S;James T;Warren F;Peck LJ;Ritter TG;de Toledo Z;Warren L;Axten D;Cornall RJ;Jones EY;Stuart DI;Screaton G;Ebner D;Hoosdally S;Chand M;Crook DW;O'Donnell AM;Conlon CP;Pouwels KB;Walker AS;Peto TEA;Hopkins S;Walker TM;Jeffery K;Eyre DW;Oxford University Hospitals Staff Testing Group
通讯作者：
Oxford University Hospitals Staff Testing Group
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
14.2
作者：
Chew, K. L.;Tan, S. S.;Sethi, S. K.
通讯作者：
Sethi, S. K.